Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 6/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1919069 | 0.93 | CYP2C8 (0.53) | CYP2C8KCNH2CYP3A4MAPTTP53 | |
| SCHEMBL144688 | 0.93 | CYP2C8 (0.53) | CYP2C8KCNH2CYP3A4MAPTTP53 | |
| SCHEMBL18751750 | 0.92 | CYP2C8 (0.52) | CYP2C8KCNH2CYP3A4MAPTTP53 | |
| SCHEMBL18751755 | 0.91 | CYP2C8 (0.55) | CYP2C8KCNH2CYP3A4MAPTKDM4E | |
| SCHEMBL10242360 | 0.90 | CYP2C8 (0.58) | CYP2C8KCNH2CYP3A4MAPTTP53 | |
| SCHEMBL1918814 | 0.90 | CYP2C8 (0.50) | CYP2C8KCNH2CYP3A4MAPTTP53 | |
| SCHEMBL1919284 | 0.90 | CYP2C8 (0.50) | CYP2C8KCNH2CYP3A4MAPTTP53 | |
| SCHEMBL254263 | 0.89 | CYP2C8 (0.49) | CYP2C8KCNH2CYP3A4MAPTTP53 | |
| SCHEMBL12447846 | 0.86 | CYP2C8 (0.52) | CYP2C8KCNH2CYP3A4MAPTKDM4E | |
| SCHEMBL1919338 | 0.86 | CYP2C8 (0.57) | CYP2C8KCNH2CYP3A4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096580-B2 | Benzofuran derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150141395-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-21 | — | — | US | disclosed |
| US-8507683-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130197012-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL MYERS SQUIBB CO (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-13 | — | — | US | disclosed |
| US-20120309770-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
| US-8309558-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| US-8148382-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141395-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HAVCR2, UGT2B7, GOT1 | CYP2C8 56/4885KCNH2 3615/4885CYP3A4 125/4885 |
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CYP2C8 85/4885KCNH2 3814/4885CYP3A4 299/4885 |
| US-20130197012-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CYP2C8 85/4885KCNH2 3814/4885CYP3A4 299/4885 |
| US-20120309770-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | CYP2C8 85/4885KCNH2 3814/4885CYP3A4 299/4885 |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, SLC10A1 | CYP2C8 85/4885KCNH2 3814/4885CYP3A4 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.